Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.

Nusshag C, Rupp C, Schmitt F, Krautkrämer E, Speer C, Kälble F, Tamulyte S, Bruckner T, Zeier M, Reiser J, Weigand MA, Uhle F, Merle U, Morath C, Brenner T.

Crit Care Med. 2019 Oct 4. doi: 10.1097/CCM.0000000000004042. [Epub ahead of print]

PMID:
31584458
2.

Pre-transplant CD200 and CD200R1 concentrations are associated with post-transplant events in kidney transplant recipients.

Oweira H, Khajeh E, Mohammadi S, Ghamarnejad O, Daniel V, Schnitzler P, Golriz M, Mieth M, Morath C, Zeier M, Mehrabi A, Sadeghi M.

Medicine (Baltimore). 2019 Sep;98(37):e17006. doi: 10.1097/MD.0000000000017006.

3.

Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.

Speer C, Kälble F, Pego da Silva L, Nusshag C, Schaier M, Becker LE, Klein K, Beimler J, Sommerer C, Leo A, Süsal C, Mehrabi A, Zeier M, Morath C.

Atheroscler Suppl. 2019 Aug 17. pii: S1567-5688(19)30053-4. doi: 10.1016/j.atherosclerosissup.2019.08.030. [Epub ahead of print]

PMID:
31447215
4.

Relevance of Donor-Specific Antibody Monitoring after Kidney Transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center.

Süsal C, Aykut G, Morath C, Fichtner A, Unterrainer C, Scherer S, Tran TH, Mehrabi A, Zeier M, Tönshoff B.

HLA. 2019 Aug 12. doi: 10.1111/tan.13665. [Epub ahead of print]

PMID:
31403240
5.

The Role of Pre-Procurement Pancreas Suitability Score (P-PASS) and Pancreas Donor Risk Index (PDRI) in the Outcome of Simultaneous Pancreas and Kidney or Pancreas After Kidney Transplantation.

Franz C, Görtz M, Wührl M, Kulu Y, Hoffmann K, Hackert T, Morath C, Zeier M, Büchler MW, Mehrabi A.

Ann Transplant. 2019 Jul 26;24:439-445. doi: 10.12659/AOT.915852.

6.

Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption - a retrospective study.

Speer C, Kälble F, Nusshag C, Pego da Silva L, Schaier M, Becker LE, Klein K, Sommerer C, Beimler J, Leo A, Waldherr R, Mehrabi A, Süsal C, Zeier M, Morath C.

Transpl Int. 2019 Jul 19. doi: 10.1111/tri.13482. [Epub ahead of print]

PMID:
31322786
7.

Prophylactic onlay reinforcement with absorbable mesh (polyglactin) is associated with less early wound complications after kidney transplantation: A preliminary study.

Michalski CW, Mohammadi S, Khajeh E, Ghamarnejad O, Sabagh M, Pianka F, Golriz M, Kulu Y, Kallinowski F, Zeier M, Morath C, Diener MK, Büchler MW, Mehrabi A.

J Biomed Mater Res B Appl Biomater. 2019 Mar 21. doi: 10.1002/jbm.b.34366. [Epub ahead of print]

PMID:
30897297
8.

Patients with idiopathic recurrent miscarriage have abnormally high TGFß+ blood NK, NKT and T cells in the presence of abnormally low TGFß plasma levels.

Zhu L, Aly M, Kuon RJ, Toth B, Wang H, Karakizlis H, Weimer R, Morath C, Ibrahim E, Ekpoom N, Opelz G, Daniel V.

BMC Immunol. 2019 Mar 4;20(1):10. doi: 10.1186/s12865-019-0290-3.

9.

Is Belatacept Switch Safe in Renal Transplant Recipients With Donor-specific Antibodies?

Süsal C, Morath C.

Transplantation. 2019 Oct;103(10):1984-1985. doi: 10.1097/TP.0000000000002588. No abstract available.

PMID:
30747836
10.

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.

Sommerer C, Zeier M, Morath C, Reiser J, Scharnagl H, Stojakovic T, Delgado GE, März W, Kleber ME.

Sci Rep. 2019 Jan 24;9(1):475. doi: 10.1038/s41598-018-36960-6.

11.

Effects of high-intensity functional circuit training on motor function and sport motivation in healthy, inactive adults.

Wilke J, Kaiser S, Niederer D, Kalo K, Engeroff T, Morath C, Vogt L, Banzer W.

Scand J Med Sci Sports. 2019 Jan;29(1):144-153. doi: 10.1111/sms.13313. Epub 2018 Oct 23.

PMID:
30276916
12.

Impact of Surgeon's Experience on Vascular and Haemorrhagic Complications After Kidney Transplantation.

Kulu Y, Fathi P, Golriz M, Khajeh E, Sabagh M, Ghamarnejad O, Mieth M, Ulrich A, Hackert T, Müller-Stich BP, Strobel O, Michalski C, Morath C, Zeier M, Büchler MW, Mehrabi A.

Eur J Vasc Endovasc Surg. 2019 Jan;57(1):139-149. doi: 10.1016/j.ejvs.2018.07.041. Epub 2018 Sep 17.

PMID:
30236441
13.

Hand-Assisted laparoscopic donor nephrectomy PERiumbilical versus Pfannenstiel incision and return to normal physical ACTivity (HAPERPACT): study protocol for a randomized controlled trial.

Kulu Y, Müller-Stich BP, Ghamarnejad O, Khajeh E, Polychronidis G, Golriz M, Nickel F, Benner L, Knebel P, Diener M, Morath C, Zeier M, Büchler MW, Mehrabi A.

Trials. 2018 Jul 13;19(1):377. doi: 10.1186/s13063-018-2775-4.

14.

Neuronal damage and shortening of lifespan in C. elegans by peritoneal dialysis fluid: Protection by glyoxalase-1.

Schlotterer A, Pfisterer F, Kukudov G, Heckmann B, Henriquez D, Morath C, Krämer BK, Hammes HP, Schwenger V, Morcos M.

Biomed Rep. 2018 Jun;8(6):540-546. doi: 10.3892/br.2018.1085. Epub 2018 Apr 3.

15.

End-stage renal disease, dialysis, kidney transplantation and their impact on CD4+ T-cell differentiation.

Schaier M, Leick A, Uhlmann L, Kälble F, Morath C, Eckstein V, Ho A, Mueller-Tidow C, Meuer S, Mahnke K, Sommerer C, Zeier M, Steinborn A.

Immunology. 2018 Oct;155(2):211-224. doi: 10.1111/imm.12947. Epub 2018 May 25.

16.

Changes of NK cell subsets with time post-transplant in peripheral blood of renal transplant recipients.

Zhu L, Aly M, Wang H, Karakizlis H, Weimer R, Morath C, Kuon RJ, Toth B, Ekpoom N, Opelz G, Daniel V.

Transpl Immunol. 2018 Aug;49:59-71. doi: 10.1016/j.trim.2018.04.005. Epub 2018 Apr 24.

PMID:
29702201
17.

Increased natural killer cell subsets with inhibitory cytokines and inhibitory surface receptors in patients with recurrent miscarriage and decreased or normal subsets in kidney transplant recipients late post-transplant.

Zhu L, Aly M, Wang H, Karakizlis H, Weimer R, Morath C, Kuon RJ, Toth B, Ekpoom N, Opelz G, Daniel V.

Clin Exp Immunol. 2018 Aug;193(2):241-254. doi: 10.1111/cei.13142. Epub 2018 May 31.

18.

Cell cycle arrest and cell death correlate with the extent of ischaemia and reperfusion injury in patients following kidney transplantation - results of an observational pilot study.

Schmitt FCF, Salgado E, Friebe J, Schmoch T, Uhle F, Fleming T, Zemva J, Kihm L, Nusshag C, Morath C, Zeier M, Bruckner T, Mehrabi A, Nawroth PP, Weigand MA, Hofer S, Brenner T.

Transpl Int. 2018 Jul;31(7):751-760. doi: 10.1111/tri.13148. Epub 2018 Mar 30.

19.

The possible critical role of T-cell help in DSA-mediated graft loss.

Süsal C, Slavcev A, Pham L, Zeier M, Morath C.

Transpl Int. 2018 Jun;31(6):577-584. doi: 10.1111/tri.13126. Epub 2018 Mar 8. Review.

20.

Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: A case report and review of the literature.

Nusshag C, Morath C, Zeier M, Weigand MA, Merle U, Brenner T.

Medicine (Baltimore). 2017 Dec;96(50):e9283. doi: 10.1097/MD.0000000000009283. Review.

21.

Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation.

Morath C, Opelz G, Döhler B, Zeier M, Süsal C.

Transplantation. 2018 May;102(5):845-852. doi: 10.1097/TP.0000000000002023.

PMID:
29215461
22.

Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial.

Sommerer C, Brocke J, Bruckner T, Schaier M, Morath C, Meuer S, Zeier M, Giese T.

Transplantation. 2018 Mar;102(3):510-520. doi: 10.1097/TP.0000000000001973.

PMID:
29077654
23.

Decreased NK cell immunity in kidney transplant recipients late post-transplant and increased NK-cell immunity in patients with recurrent miscarriage.

Zhu L, Aly M, Wang H, Karakizlis H, Weimer R, Morath C, Kuon RJ, Toth B, Opelz G, Daniel V.

PLoS One. 2017 Oct 17;12(10):e0186349. doi: 10.1371/journal.pone.0186349. eCollection 2017.

24.

Endothelial precursor cell cross-match using Tie-2-enriched spleen cells.

Daniel V, Süsal C, Scherer S, Tran H, Gombos P, Trojan K, Sadeghi M, Morath C, Opelz G.

Clin Transplant. 2017 Dec;31(12). doi: 10.1111/ctr.13118. Epub 2017 Oct 12.

PMID:
28925558
25.

Low utility of serum 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 in predicting peripheral Treg and Th17 cell counts in ESRD and renal transplant patients.

Aly MG, Zhu L, Weimer R, Opelz G, Morath C, Kuon R, Tohamy M, Saadi G, Soliman M, Ibrahim W, Daniel V.

Transpl Immunol. 2017 Aug;43-44:3-10. doi: 10.1016/j.trim.2017.07.003. Epub 2017 Jul 27.

PMID:
28757397
26.

Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study.

Süsal C, Fichtner A, Tönshoff B, Mehrabi A, Zeier M, Morath C.

J Immunol Res. 2017;2017:5619402. doi: 10.1155/2017/5619402. Epub 2017 Jun 4. Review.

27.

Issues of Acute Kidney Injury Staging and Management in Sepsis and Critical Illness: A Narrative Review.

Nusshag C, Weigand MA, Zeier M, Morath C, Brenner T.

Int J Mol Sci. 2017 Jun 28;18(7). pii: E1387. doi: 10.3390/ijms18071387. Review.

28.

Increased risk of infection-associated death with incompatible kidney transplantations.

Morath C, Zeier M, Süsal C.

Transpl Int. 2017 Dec;30(12):1209-1211. doi: 10.1111/tri.12995. No abstract available.

29.

Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.

Kälble F, Seckinger J, Schaier M, Morath C, Schwenger V, Zeier M, Sommerer C.

Clin Transplant. 2017 Aug;31(8). doi: 10.1111/ctr.13024. Epub 2017 Jul 7.

PMID:
28581202
30.

Correction: Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft function.

Trojan K, Unterrainer C, Weimer R, Bulut N, Morath C, Aly M, Zhu L, Opelz G, Daniel V.

PLoS One. 2017 May 31;12(5):e0179069. doi: 10.1371/journal.pone.0179069. eCollection 2017.

31.

An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.

Kälble F, Schaier M, Schäfer S, Süsal C, Zeier M, Sommerer C, Morath C.

Expert Opin Pharmacother. 2017 Jun;18(8):799-807. doi: 10.1080/14656566.2017.1323876. Epub 2017 May 9. Review.

PMID:
28460546
32.

ABO-Incompatible Kidney Transplantation.

Morath C, Zeier M, Döhler B, Opelz G, Süsal C.

Front Immunol. 2017 Mar 6;8:234. doi: 10.3389/fimmu.2017.00234. eCollection 2017. Review.

33.

Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft function.

Trojan K, Unterrainer C, Weimer R, Bulut N, Morath C, Aly M, Zhu L, Opelz G, Daniel V.

PLoS One. 2017 Mar 15;12(3):e0173773. doi: 10.1371/journal.pone.0173773. eCollection 2017. Erratum in: PLoS One. 2017 May 31;12 (5):e0179069.

34.

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Morath C, Schmitt A, Kälble F, Zeier M, Schmitt M, Sandra-Petrescu F, Opelz G, Terness P, Schaier M, Kleist C.

Pediatr Nephrol. 2018 Feb;33(2):199-213. doi: 10.1007/s00467-017-3599-2. Epub 2017 Feb 23. Review.

PMID:
28229281
35.

Association of peripheral NK cell counts with Helios+ IFN-γ- Tregs in patients with good long-term renal allograft function.

Trojan K, Zhu L, Aly M, Weimer R, Bulut N, Morath C, Opelz G, Daniel V.

Clin Exp Immunol. 2017 Jun;188(3):467-479. doi: 10.1111/cei.12945. Epub 2017 Mar 13.

36.

IFNy+ and IFNy- Treg subsets with stable and unstable Foxp3 expression in kidney transplant recipients with good long-term graft function.

Trojan K, Unterrainer C, Aly M, Zhu L, Weimer R, Bulut N, Morath C, Opelz G, Daniel V.

Transpl Immunol. 2016 Oct 29. pii: S0966-3274(16)30124-1. doi: 10.1016/j.trim.2016.10.003. [Epub ahead of print]

PMID:
27989714
37.

Tissue Expression of Aquaporin 2 Is Correlated to Urine Output and Allograft Function in Sensitized Kidney Transplant Patients.

Klein K, Rübenacker S, Schaefer SM, Kihm LP, Schwenger V, Macher-Goeppinger S, Schemmer P, Süsald C, Zeier M, Morath C, Becker LE.

Transplant Proc. 2016 Oct;48(8):2629-2636. doi: 10.1016/j.transproceed.2016.06.056.

PMID:
27788793
38.

Donor-specific antibodies require preactivated immune system to harm renal transplant.

Süsal C, Döhler B, Ruhenstroth A, Morath C, Slavcev A, Fehr T, Wagner E, Krüger B, Rees M, Balen S, Živčić-Ćosić S, Norman DJ, Kuypers D, Emonds MP, Pisarski P, Bösmüller C, Weimer R, Mytilineos J, Scherer S, Tran TH, Gombos P, Schemmer P, Zeier M, Opelz G; A Collaborative Transplant Study Report.

EBioMedicine. 2016 Jul;9:366-371. doi: 10.1016/j.ebiom.2016.06.006. Epub 2016 Jun 5.

39.

Low-dose oral cholecalciferol is associated with higher numbers of Helios(+) and total Tregs than oral calcitriol in renal allograft recipients: an observational study.

Aly MG, Trojan K, Weimer R, Morath C, Opelz G, Tohamy MA, Daniel V.

BMC Pharmacol Toxicol. 2016 Jun 14;17(1):24. doi: 10.1186/s40360-016-0066-9.

40.

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey.

Assfalg V, Hüser N, van Meel M, Haller B, Rahmel A, de Boer J, Matevossian E, Novotny A, Knops N, Weekers L, Friess H, Pratschke J, Függer R, Janko O, Rasoul-Rockenschaub S, Bosmans JL, Broeders N, Peeters P, Mourad M, Kuypers D, Slaviček J, Muehlfeld A, Sommer F, Viebahn R, Pascher A, van der Giet M, Zantvoort F, Woitas RP, Putz J, Grabitz K, Kribben A, Hauser I, Pisarski P, Weimer R, Lorf T, Fornara P, Morath C, Nashan B, Lehner F, Kliem V, Sester U, Grimm MO, Feldkamp T, Kleinert R, Arns W, Mönch C, Schoenberg MB, Nitschke M, Krüger B, Thorban S, Arbogast HP, Wolters HH, Maier T, Lutz J, Heller K, Banas B, Hakenberg O, Kalus M, Nadalin S, Keller F, Lopau K, Bemelman FJ, Nurmohamed S, Sanders JS, de Fijter JW, Christiaans M, Hilbrands L, Betjes M, van Zuilen A, Heemann U.

Nephrol Dial Transplant. 2016 Sep;31(9):1515-22. doi: 10.1093/ndt/gfv446. Epub 2016 Feb 4.

41.

Immune mechanisms of acute and chronic rejection.

Becker LE, Morath C, Suesal C.

Clin Biochem. 2016 Mar;49(4-5):320-3. doi: 10.1016/j.clinbiochem.2016.02.001. Epub 2016 Feb 3. Review.

PMID:
26851348
42.

Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.

Schaefer SM, Süsal C, Opelz G, Döhler B, Becker LE, Klein K, Sickmüller S, Waldherr R, Macher-Goeppinger S, Schemmer P, Beimler J, Zeier M, Morath C.

HLA. 2016 Feb;87(2):89-99. doi: 10.1111/tan.12735. Epub 2016 Feb 3.

PMID:
26840927
43.

A fast and simple method for detecting and quantifying donor-derived cell-free DNA in sera of solid organ transplant recipients as a biomarker for graft function.

Adamek M, Opelz G, Klein K, Morath C, Tran TH.

Clin Chem Lab Med. 2016 Jul 1;54(7):1147-55. doi: 10.1515/cclm-2015-0622.

PMID:
26574891
44.

Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts.

Daniel V, Sadeghi M, Suesal C, Scherer S, Tran H, Gombos P, Trojan K, Morath C, Opelz G.

Clin Transplant. 2016 Feb;30(2):124-30. doi: 10.1111/ctr.12665. Epub 2015 Dec 16.

PMID:
26537026
45.

A Single-center Experience on the Value of Pancreas Graft Biopsies and HLA Antibody Monitoring After Simultaneous Pancreas-Kidney Transplantation.

Becker LE, Hallscheidt P, Schaefer SM, Klein K, Grenacher L, Waldherr R, Macher-Goeppinger S, Schemmer P, Mehrabi A, Suesal C, Zeier M, Morath C.

Transplant Proc. 2015 Oct;47(8):2504-12. doi: 10.1016/j.transproceed.2015.09.013.

PMID:
26518960
46.

Response to A reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation.

Morath C, Zeier M, Süsal C, Döhler B, Opelz G.

Transplantation. 2015 Nov;99(11):e175. doi: 10.1097/TP.0000000000000839. No abstract available.

PMID:
26492056
47.

Long-Term Follow-Up of Kidney Transplant Recipients With Polycystic Kidney Disease.

Mehrabi A, Golriz M, Maier J, Fonouni H, Garoussi C, Hafezi M, Fard N, Faridar A, Rezaei N, Wiesel M, Mieth M, Morath C, Büchler MW, Tönshoff B, Zeier M, Schmidt J, Schemmer P.

Exp Clin Transplant. 2015 Oct;13(5):413-20.

48.

Cell therapy for immunosuppression after kidney transplantation.

Morath C, Schmitt A, Zeier M, Schmitt M, Sandra-Petrescu F, Opelz G, Terness P, Schaier M, Kleist C.

Langenbecks Arch Surg. 2015 Jul;400(5):541-50. doi: 10.1007/s00423-015-1313-z. Epub 2015 Jun 17. Review.

PMID:
26077202
49.

Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.

Becker LE, Siebert D, Süsal C, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C.

Transplantation. 2015 Nov;99(11):2364-71. doi: 10.1097/TP.0000000000000753.

PMID:
25989497
50.

Virtual PRA replaces traditional PRA: small change but significantly more justice for sensitized patients.

Süsal C, Morath C.

Transpl Int. 2015 Jun;28(6):708-9. doi: 10.1111/tri.12572. No abstract available.

Supplemental Content

Loading ...
Support Center